Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US

被引：0
|
作者：
Sai Zhang
Nathaniel D. Bastian
Paul M. Griffin
机构：
[1] Georgia Institute of Technology,School of Industrial and Systems Engineering
[2] Penn State University,Department of Industrial Engineering
来源：
BMC Gastroenterology | / 15卷
关键词：
Cost-effectiveness; Markov model; Sofosbuvir; Harvoni; Olysio; Viekira Pak; Chronic hepatitis C;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 US Veterans
    Backus, L. I.
    Belperio, P. S.
    Shahoumian, T. A.
    Loomis, T. P.
    Mole, L. A.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (05) : 559 - 573
  • [32] COST-EFFECTIVENESS ANALYSIS OF SOFOSBUVIR FOR GENOTYPE 2 HEPATITIS C IN GREECE
    Athanasakis, K.
    Boubouchairopoulou, N.
    Kyriopoulos, I
    Tsoulas, C.
    Tzanakis, B.
    Kyriopoulos, J.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A415 - A415
  • [33] Cost-effectiveness of treatment for chronic hepatitis C
    Koff, RS
    [J]. JOURNAL OF HEPATOLOGY, 1999, 31 : 255 - 258
  • [34] Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C in Severe Renal Dysfunction
    Cox-North, Paula
    Hawkins, Kelsey L.
    Rossiter, Sean T.
    Hawley, Marie N.
    Bhattacharya, Renuka
    Landis, Charles S.
    [J]. HEPATOLOGY COMMUNICATIONS, 2017, 1 (03) : 248 - 255
  • [35] Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis
    Choudhary N.S.
    Kumar A.
    Bodh V.
    Bansal S.B.
    Sharma R.
    Jain M.
    Saigal S.
    Saraf N.
    [J]. Indian Journal of Gastroenterology, 2017, 36 (2) : 113 - 116
  • [36] Efficacy and safety of sofosbuvir-based therapy for aged patients with chronic hepatitis C
    Urabe, Ayako
    Sakamori, Ryotaro
    Tatsumi, Tomohide
    Yakushijin, Takayuki
    Yamada, Ryoko
    Oze, Tsugiko
    Morishita, Naoki
    Tahata, Yuki
    Hosui, Atsushi
    Miyagi, Takuya
    Doi, Yoshinori
    Kaneko, Akira
    Oshita, Masahide
    Hagiwara, Hideki
    Yamada, Yukinori
    Tamura, Shinji
    Imai, Yasuharu
    Furuta, Kunimaro
    Hikita, Hayato
    Hiramatsu, Naoki
    Hayashi, Norio
    Takehara, Tetsuo
    [J]. HEPATOLOGY, 2016, 64 : 996A - 997A
  • [37] Effectiveness and safety of sofosbuvir-based therapy against chronic hepatitis C infection after successful kidney transplantation
    Musialik, Joanna
    Kolonko, Aureliusz
    Kwiecien, Katarzyna
    Owczarek, Aleksander J.
    Wiecek, Andrzej
    [J]. TRANSPLANT INFECTIOUS DISEASE, 2019, 21 (03)
  • [38] COST-EFFECTIVENESS ANALYSIS OF HIGHLY INNOVATIVE TREATMENTS FOR HEPATITIS C: THE CASE OF LEDIPASVIR/SOFOSBUVIR IN A GREEK HEALTHCARE SETTING
    Athanasakis, K.
    Boubouchairopoulou, N.
    Kyriopoulos, I
    Tsoulas, C.
    Tzanakis, B.
    Kyriopoulos, J.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A413 - A414
  • [39] COST-EFFECTIVENESS OF LEDIPASVIR/SOFOSBUVIR FOR THE TREATMENT OF GENOTYPE 1 OR 4 CHRONIC HEPATITIS C IN ENGLAND AND WALES
    Howells, R.
    Trehame, C.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A589 - A589
  • [40] Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy
    Cure, Sandrine
    Guerra, Ines
    Camma, Calogero
    Craxi, Antonio
    Carosi, Giampiero
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (09) : 678 - 690
12345